A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)

Systemic Lupus Erythematosus Clinical Trial

— BEGIN  

Official title:

A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00539838
• Other study ID #: ACT4071g
• Secondary ID: WA20499
• Status: Terminated
• Phase: Phase 3
• Start date: December 19, 2007
• Est. completion date: July 12, 2011

Study information

• Verified date: August 2020
• Source: Genentech, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase III, randomized, double blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of ocrelizumab compared to placebo when combined with a single stable background immunosuppressive medication and a corticosteroid regimen in patients with moderately to severely active systemic lupus erythematosus, who do not have moderate to severe glomerulonephritis.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 33
• Est. completion date: July 12, 2011
• Est. primary completion date: July 12, 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

• Age 16 years or above at the time of screening

• Diagnosis of SLE

• Active disease at screening

Exclusion Criteria:

• Presence of active moderate to severe glomerulonephritis

• Currently active retinitis, poorly controlled seizure disorder, acute confusional state, myelitis, stroke or stroke syndrome, cerebellar ataxia, or dementia

• Lack of peripheral venous access

• Pregnancy or breast feeding mothers

• History of severe allergic or anaphylactic reactions to humanized, chimeric or murine monoclonal antibodies or i.v. immunoglobulin

• Known severe chronic pulmonary disease

• Evidence of significant or uncontrolled concomitant diseases in any organ system not related to SLE, which, in the investigator's opinion, would impair patient participation

• Concomitant condition which has required treatment with systemic corticosteroid (excluding topical or inhaled) at any time in the 52 weeks prior to screening

• Known HIV or chronic active Hepatitis B or chronic active Hepatitis C infection

• Known active infection of any kind (but excluding fungal infection of nail beds or oral thrush which has resolved before Day 1) within 30 days prior to Day 1. In addition, any major episode of infection requiring hospitalization or treatment with intravenous anti-infectives in the 30 days prior to Day 1 or oral anti-infectives in the 14 days prior to Day 1

• History of serious recurrent or chronic infection

• History of cancer (except basal cell carcinoma of the skin that has been excised and cured)

• History of alcohol or drug abuse in the 52 weeks prior to screening

• Major surgery in the 4 weeks prior to screening excluding diagnostic surgery

• Previous treatment with CAMPATH-1H

• Previous treatment with a BAFF directed treatment in the 12 months prior to screening

• Previous treatment with a B-cell targeted therapy other than one directed at BAFF

• Treatment with any investigational agent, other than those above, in the 28 days prior to screening or five half-lives of the investigational drug (whichever is longer)

• Receipt of any live vaccine in the 6 weeks prior to Day 1

• Intolerance or contraindication to oral or i.v. corticosteroids

• Treatment with a second immunosuppressive or immunomodulatory drug in the 8 weeks prior to Day 1

• Prednisone dose of = 0.7 mg/kg/day (or equivalent) for > 7 of the previous 30 days prior to screening

• Treatment with cyclophosphamide or a calcineurin inhibitor in the 12 weeks prior to screening

• Positive hepatitis BsAg or hepatitis C serology. Patients who are HBsAg negative but HBcAb positive may be enrolled with a negative DNA test

Related Conditions & MeSH terms

• Lupus Erythematosus, Systemic
• Systemic Lupus Erythematosus

Intervention

Drug:
• Prednisone
Oral repeating dose
• Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate)
Oral repeating dose
• Methylprednisolone
Intravenous repeating dose
• Ocrelizumab
Intravenous repeating dose
• Placebo
Intravenous repeating dose

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Genentech, Inc.	Roche Pharma AG

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Major Clinical Response (MCR)		Week 48
Primary	Number of Participants With Partial Clinical Response (PCR)		Week 48
Primary	Number of Non-responders (NR)		Week 48
Secondary	Number of Participants Who Achieved a BILAG Score of C or Better at Week 24.		Week 24
Secondary	Time Adjusted Mean SLEDAI-2K Score		Week 48
Secondary	Annualized Flare Rate		Week 48 to Week 96
Secondary	Time to First Moderate to Severe Flare		Week 48 to Week 96
Secondary	Number of Participants Who Achieved A Major Or Partial Clinical Response At Week 48 (PCR Plus MCR Proportion), Who Did Not Experience A Flare Before Week 96		Week 48 to Week 96
Secondary	Number of Participants Who Achieved A MCR At Week 48, Who Did Not Experience A Flare Before Week 72		Week 48 to Week 72
Secondary	Number of Participants Achieved A MCR At Week 48, Who Did Not Experience A Flare Before Week 96		Week 48 to Week 96
Secondary	Change in SF-36 Subscale And Summary Scores From Baseline At Week 48		Baseline, Week 48
Secondary	Change In FACIT-Fatigue Assessment From Baseline To Week 48		Baseline, Week 48
Secondary	Change From Baseline In Pain Quality And Impact Of Pain On Daily Function Measured By The Brief Pain Inventory Short Form At Week 48		Baseline, Week 48
Secondary	The EQ-5D Single Index Utility Score At Week 48		Baseline, Week 48
Secondary	Number of Participants With Adverse Events		Up to 2.5 years

External Links

•   Ex-U.S. Study Information (Ex-US this trial is sponsored/managed by Hoffmann-La Roche)